Click for best price
RadiopharmaceuticalsNuclear Medicine Market Size, Share 2022
Market Analysis and Insights: Global RadiopharmaceuticalsNuclear Medicine Market
The global RadiopharmaceuticalsNuclear Medicine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global RadiopharmaceuticalsNuclear Medicine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global RadiopharmaceuticalsNuclear Medicine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global RadiopharmaceuticalsNuclear Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global RadiopharmaceuticalsNuclear Medicine market.
Global RadiopharmaceuticalsNuclear Medicine Scope and Market Size
Radiopharmaceuticals in Nuclear Medicine market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Radiopharmaceuticals in Nuclear Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Radiopharmaceuticals in Nuclear Medicine market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes RadiopharmaceuticalsNuclear Medicine product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of RadiopharmaceuticalsNuclear Medicine, with price, sales, revenue, and global market share of RadiopharmaceuticalsNuclear Medicine from 2019 to 2022.
Chapter 3, the RadiopharmaceuticalsNuclear Medicine competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the RadiopharmaceuticalsNuclear Medicine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the RadiopharmaceuticalsNuclear Medicine market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of RadiopharmaceuticalsNuclear Medicine.
Chapter 13, 14, and 15, to describe RadiopharmaceuticalsNuclear Medicine sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 RadiopharmaceuticalsNuclear Medicine Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Radiopharmaceuticals in Nuclear Medicine Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
123 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Radiopharmaceuticals in Nuclear Medicine Product Introduction
1.2 Global Radiopharmaceuticals in Nuclear Medicine Outlook 2017 VS 2022 VS 2028
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in US$ Million for the Year 2017-2028
1.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume for the Year 2017-2028
1.3 United States Radiopharmaceuticals in Nuclear Medicine Outlook 2017 VS 2022 VS 2028
1.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales in US$ Million for the Year 2017-2028
1.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales in Volume for the Year 2017-2028
1.4 Radiopharmaceuticals in Nuclear Medicine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Radiopharmaceuticals in Nuclear Medicine in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Radiopharmaceuticals in Nuclear Medicine Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
1.5.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
1.5.2 Radiopharmaceuticals in Nuclear Medicine Market Drivers
1.5.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
1.5.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Radiopharmaceuticals in Nuclear Medicine Market Segment by Type
2.1.1 Diagnostic Radiopharmaceuticals
2.1.2 Therapy Radiopharmaceuticals
2.1.3 Enriched Stable Isotopes
2.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Type
2.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Radiopharmaceuticals in Nuclear Medicine Market Size by Type
2.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Radiopharmaceuticals in Nuclear Medicine Market Segment by Application
3.1.1 Diagnostic Application
3.1.2 Therapeutic Application
3.1.3 Research
3.1.4 Pharmaceutical
3.1.5 Other
3.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Application
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Radiopharmaceuticals in Nuclear Medicine Market Size by Application
3.3.1 United States Radiopharmaceuticals in Nuclear Medicine Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Radiopharmaceuticals in Nuclear Medicine Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Radiopharmaceuticals in Nuclear Medicine Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Radiopharmaceuticals in Nuclear Medicine Competitor Landscape by Company
4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Company
4.1.1 Top Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Ranked by Revenue (2021)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturer (2017-2022)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturer (2017-2022)
4.1.4 Global Radiopharmaceuticals in Nuclear Medicine Price by Manufacturer (2017-2022)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Concentration Ratio (CR)
4.2.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Radiopharmaceuticals in Nuclear Medicine in 2021
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Manufacturing Base Distribution, Product Type
4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
4.3.3 Date of International Manufacturers Enter into Radiopharmaceuticals in Nuclear Medicine Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Radiopharmaceuticals in Nuclear Medicine Market Size by Company
4.5.1 Top Radiopharmaceuticals in Nuclear Medicine Players in United States, Ranked by Revenue (2021)
4.5.2 United States Radiopharmaceuticals in Nuclear Medicine Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Radiopharmaceuticals in Nuclear Medicine Sales by Players (2020, 2021 & 2022)
5 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region
5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size in Volume by Region (2017-2028)
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region: 2017-2022
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume Forecast by Region (2023-2028)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size in Value by Region (2017-2028)
5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region: 2017-2022
5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.1.2 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.4.2 Latin America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Bracco Imaging S.P.A.
7.1.1 Bracco Imaging S.P.A. Corporation Information
7.1.2 Bracco Imaging S.P.A. Description and Business Overview
7.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.1.5 Bracco Imaging S.P.A. Recent Development
7.2 Cambridge Isotope Laboratories, Inc.
7.2.1 Cambridge Isotope Laboratories, Inc. Corporation Information
7.2.2 Cambridge Isotope Laboratories, Inc. Description and Business Overview
7.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.2.5 Cambridge Isotope Laboratories, Inc. Recent Development
7.3 Cardinal Health, Inc.
7.3.1 Cardinal Health, Inc. Corporation Information
7.3.2 Cardinal Health, Inc. Description and Business Overview
7.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.3.5 Cardinal Health, Inc. Recent Development
7.4 Covidien, Plc
7.4.1 Covidien, Plc Corporation Information
7.4.2 Covidien, Plc Description and Business Overview
7.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Products Offered
7.4.5 Covidien, Plc Recent Development
7.5 Eczacibasi-Monrol
7.5.1 Eczacibasi-Monrol Corporation Information
7.5.2 Eczacibasi-Monrol Description and Business Overview
7.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Products Offered
7.5.5 Eczacibasi-Monrol Recent Development
7.6 Fujifilm Holdings Corporation
7.6.1 Fujifilm Holdings Corporation Corporation Information
7.6.2 Fujifilm Holdings Corporation Description and Business Overview
7.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Products Offered
7.6.5 Fujifilm Holdings Corporation Recent Development
7.7 GE Healthcare (Subsidiary Of General Electric Company)
7.7.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
7.7.2 GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
7.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.7.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Products Offered
7.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Development
7.8 IBA Group
7.8.1 IBA Group Corporation Information
7.8.2 IBA Group Description and Business Overview
7.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Products Offered
7.8.5 IBA Group Recent Development
7.9 Isotec, Inc. (Sigma-Aldrich)
7.9.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
7.9.2 Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
7.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Products Offered
7.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Development
7.10 Lantheus Medical Imaging, Inc.
7.10.1 Lantheus Medical Imaging, Inc. Corporation Information
7.10.2 Lantheus Medical Imaging, Inc. Description and Business Overview
7.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.10.5 Lantheus Medical Imaging, Inc. Recent Development
7.11 Nordion, Inc.
7.11.1 Nordion, Inc. Corporation Information
7.11.2 Nordion, Inc. Description and Business Overview
7.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Products Offered
7.11.5 Nordion, Inc. Recent Development
7.12 Ntp Radioisotopes (Pty), Ltd.
7.12.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
7.12.2 Ntp Radioisotopes (Pty), Ltd. Description and Business Overview
7.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Ntp Radioisotopes (Pty), Ltd. Products Offered
7.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Development
7.13 Siemens Healthcare (Subsidiary Of Siemens AG)
7.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
7.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Description and Business Overview
7.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Products Offered
7.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Development
7.14 Taiyo Nippon Sanso Corporation
7.14.1 Taiyo Nippon Sanso Corporation Corporation Information
7.14.2 Taiyo Nippon Sanso Corporation Description and Business Overview
7.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Taiyo Nippon Sanso Corporation Products Offered
7.14.5 Taiyo Nippon Sanso Corporation Recent Development
7.15 Urenco Limited
7.15.1 Urenco Limited Corporation Information
7.15.2 Urenco Limited Description and Business Overview
7.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Urenco Limited Products Offered
7.15.5 Urenco Limited Recent Development
7.16 Rotem Industries, Ltd., Inc.
7.16.1 Rotem Industries, Ltd., Inc. Corporation Information
7.16.2 Rotem Industries, Ltd., Inc. Description and Business Overview
7.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.16.4 Rotem Industries, Ltd., Inc. Products Offered
7.16.5 Rotem Industries, Ltd., Inc. Recent Development
7.17 Australian Nuclear Association And Technology Organization (ANSTO)
7.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
7.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Description and Business Overview
7.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Products Offered
7.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Development
7.18 Board of Radiation And Isotope Technology (BRIT)
7.18.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
7.18.2 Board of Radiation And Isotope Technology (BRIT) Description and Business Overview
7.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.18.4 Board of Radiation And Isotope Technology (BRIT) Products Offered
7.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Development
7.19 Institute of Atomic Energy Polatom Radioisotope Centre
7.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
7.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Description and Business Overview
7.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Products Offered
7.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Development
7.20 Institute of Isotopes Co., Ltd.
7.20.1 Institute of Isotopes Co., Ltd. Corporation Information
7.20.2 Institute of Isotopes Co., Ltd. Description and Business Overview
7.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.20.4 Institute of Isotopes Co., Ltd. Products Offered
7.20.5 Institute of Isotopes Co., Ltd. Recent Development
7.21 Institute Of Radioelement (IRE)
7.21.1 Institute Of Radioelement (IRE) Corporation Information
7.21.2 Institute Of Radioelement (IRE) Description and Business Overview
7.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2017-2022)
7.21.4 Institute Of Radioelement (IRE) Products Offered
7.21.5 Institute Of Radioelement (IRE) Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
8.2 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
8.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
8.4 Radiopharmaceuticals in Nuclear Medicine Sales and Marketing
8.4.1 Radiopharmaceuticals in Nuclear Medicine Sales Channels
8.4.2 Radiopharmaceuticals in Nuclear Medicine Distributors
8.5 Radiopharmaceuticals in Nuclear Medicine Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Radiopharmaceuticals in Nuclear Medicine CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Radiopharmaceuticals in Nuclear Medicine Market Trends
Table 3. Radiopharmaceuticals in Nuclear Medicine Market Drivers
Table 4. Radiopharmaceuticals in Nuclear Medicine Market Challenges
Table 5. Radiopharmaceuticals in Nuclear Medicine Market Restraints
Table 6. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Radiopharmaceuticals in Nuclear Medicine Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Radiopharmaceuticals in Nuclear Medicine Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Radiopharmaceuticals in Nuclear Medicine Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Radiopharmaceuticals in Nuclear Medicine Revenue Share by Manufacturer, 2017-2022
Table 13. Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturer, (K MT), 2017-2022
Table 14. Global Radiopharmaceuticals in Nuclear Medicine Sales Share by Manufacturer, 2017-2022
Table 15. Global Radiopharmaceuticals in Nuclear Medicine Price by Manufacturer (2017-2022) & (USD/MT)
Table 16. Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Radiopharmaceuticals in Nuclear Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radiopharmaceuticals in Nuclear Medicine as of 2021)
Table 18. Top Players of Radiopharmaceuticals in Nuclear Medicine in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Radiopharmaceuticals in Nuclear Medicine Product Type
Table 20. Date of International Manufacturers Enter into Radiopharmaceuticals in Nuclear Medicine Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Radiopharmaceuticals in Nuclear Medicine Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Radiopharmaceuticals in Nuclear Medicine Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Radiopharmaceuticals in Nuclear Medicine Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Radiopharmaceuticals in Nuclear Medicine Sales by Players, (K MT), 2020, 2021 & 2022
Table 26. United States Radiopharmaceuticals in Nuclear Medicine Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2017-2022) & (K MT)
Table 29. Global Radiopharmaceuticals in Nuclear Medicine Sales in Volume Forecast by Region (2023-2028) & (K MT)
Table 30. Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Radiopharmaceuticals in Nuclear Medicine Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2017-2028) & (K MT)
Table 33. North America Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Region (2017-2028) & (K MT)
Table 35. Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2017-2028) & (K MT)
Table 37. Europe Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2017-2028) & (K MT)
Table 39. Latin Americaa Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales in Volume by Country (2017-2028) & (K MT)
Table 41. Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Bracco Imaging S.P.A. Corporation Information
Table 43. Bracco Imaging S.P.A. Description and Business Overview
Table 44. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 45. Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product
Table 46. Bracco Imaging S.P.A. Recent Development
Table 47. Cambridge Isotope Laboratories, Inc. Corporation Information
Table 48. Cambridge Isotope Laboratories, Inc. Description and Business Overview
Table 49. Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 50. Cambridge Isotope Laboratories, Inc. Product
Table 51. Cambridge Isotope Laboratories, Inc. Recent Development
Table 52. Cardinal Health, Inc. Corporation Information
Table 53. Cardinal Health, Inc. Description and Business Overview
Table 54. Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 55. Cardinal Health, Inc. Product
Table 56. Cardinal Health, Inc. Recent Development
Table 57. Covidien, Plc Corporation Information
Table 58. Covidien, Plc Description and Business Overview
Table 59. Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 60. Covidien, Plc Product
Table 61. Covidien, Plc Recent Development
Table 62. Eczacibasi-Monrol Corporation Information
Table 63. Eczacibasi-Monrol Description and Business Overview
Table 64. Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 65. Eczacibasi-Monrol Product
Table 66. Eczacibasi-Monrol Recent Development
Table 67. Fujifilm Holdings Corporation Corporation Information
Table 68. Fujifilm Holdings Corporation Description and Business Overview
Table 69. Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 70. Fujifilm Holdings Corporation Product
Table 71. Fujifilm Holdings Corporation Recent Development
Table 72. GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
Table 73. GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
Table 74. GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 75. GE Healthcare (Subsidiary Of General Electric Company) Product
Table 76. GE Healthcare (Subsidiary Of General Electric Company) Recent Development
Table 77. IBA Group Corporation Information
Table 78. IBA Group Description and Business Overview
Table 79. IBA Group Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 80. IBA Group Product
Table 81. IBA Group Recent Development
Table 82. Isotec, Inc. (Sigma-Aldrich) Corporation Information
Table 83. Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
Table 84. Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 85. Isotec, Inc. (Sigma-Aldrich) Product
Table 86. Isotec, Inc. (Sigma-Aldrich) Recent Development
Table 87. Lantheus Medical Imaging, Inc. Corporation Information
Table 88. Lantheus Medical Imaging, Inc. Description and Business Overview
Table 89. Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 90. Lantheus Medical Imaging, Inc. Product
Table 91. Lantheus Medical Imaging, Inc. Recent Development
Table 92. Nordion, Inc. Corporation Information
Table 93. Nordion, Inc. Description and Business Overview
Table 94. Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 95. Nordion, Inc. Product
Table 96. Nordion, Inc. Recent Development
Table 97. Ntp Radioisotopes (Pty), Ltd. Corporation Information
Table 98. Ntp Radioisotopes (Pty), Ltd. Description and Business Overview
Table 99. Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 100. Ntp Radioisotopes (Pty), Ltd. Product
Table 101. Ntp Radioisotopes (Pty), Ltd. Recent Development
Table 102. Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
Table 103. Siemens Healthcare (Subsidiary Of Siemens AG) Description and Business Overview
Table 104. Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 105. Siemens Healthcare (Subsidiary Of Siemens AG) Product
Table 106. Siemens Healthcare (Subsidiary Of Siemens AG) Recent Development
Table 107. Taiyo Nippon Sanso Corporation Corporation Information
Table 108. Taiyo Nippon Sanso Corporation Description and Business Overview
Table 109. Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 110. Taiyo Nippon Sanso Corporation Product
Table 111. Taiyo Nippon Sanso Corporation Recent Development
Table 112. Urenco Limited Corporation Information
Table 113. Urenco Limited Description and Business Overview
Table 114. Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 115. Urenco Limited Product
Table 116. Urenco Limited Recent Development
Table 117. Rotem Industries, Ltd., Inc. Corporation Information
Table 118. Rotem Industries, Ltd., Inc. Description and Business Overview
Table 119. Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 120. Rotem Industries, Ltd., Inc. Product
Table 121. Rotem Industries, Ltd., Inc. Recent Development
Table 122. Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
Table 123. Australian Nuclear Association And Technology Organization (ANSTO) Description and Business Overview
Table 124. Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 125. Australian Nuclear Association And Technology Organization (ANSTO) Product
Table 126. Australian Nuclear Association And Technology Organization (ANSTO) Recent Development
Table 127. Board of Radiation And Isotope Technology (BRIT) Corporation Information
Table 128. Board of Radiation And Isotope Technology (BRIT) Description and Business Overview
Table 129. Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 130. Board of Radiation And Isotope Technology (BRIT) Product
Table 131. Board of Radiation And Isotope Technology (BRIT) Recent Development
Table 132. Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
Table 133. Institute of Atomic Energy Polatom Radioisotope Centre Description and Business Overview
Table 134. Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 135. Institute of Atomic Energy Polatom Radioisotope Centre Product
Table 136. Institute of Atomic Energy Polatom Radioisotope Centre Recent Development
Table 137. Institute of Isotopes Co., Ltd. Corporation Information
Table 138. Institute of Isotopes Co., Ltd. Description and Business Overview
Table 139. Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 140. Institute of Isotopes Co., Ltd. Product
Table 141. Institute of Isotopes Co., Ltd. Recent Development
Table 142. Institute Of Radioelement (IRE) Corporation Information
Table 143. Institute Of Radioelement (IRE) Description and Business Overview
Table 144. Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 145. Institute Of Radioelement (IRE) Product
Table 146. Institute Of Radioelement (IRE) Recent Development
Table 147. Key Raw Materials Lists
Table 148. Raw Materials Key Suppliers Lists
Table 149. Radiopharmaceuticals in Nuclear Medicine Customers List
Table 150. Radiopharmaceuticals in Nuclear Medicine Distributors List
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Radiopharmaceuticals in Nuclear Medicine Product Picture
Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Radiopharmaceuticals in Nuclear Medicine Market Size 2017-2028 (US$ Million)
Figure 4. Global Radiopharmaceuticals in Nuclear Medicine Sales 2017-2028 (K MT)
Figure 5. United States Radiopharmaceuticals in Nuclear Medicine Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Radiopharmaceuticals in Nuclear Medicine Market Size 2017-2028 (US$ Million)
Figure 7. United States Radiopharmaceuticals in Nuclear Medicine Sales 2017-2028 (K MT)
Figure 8. United States Radiopharmaceuticals in Nuclear Medicine Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Radiopharmaceuticals in Nuclear Medicine Market Share in Global, in Volume (K MT) 2017-2028
Figure 10. Radiopharmaceuticals in Nuclear Medicine Report Years Considered
Figure 11. Product Picture of Diagnostic Radiopharmaceuticals
Figure 12. Product Picture of Therapy Radiopharmaceuticals
Figure 13. Product Picture of Enriched Stable Isotopes
Figure 14. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Type in 2022 & 2028
Figure 15. Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Type (2017-2028) & (US$ Million)
Figure 16. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Value by Type (2017-2028)
Figure 17. Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028) & (K MT)
Figure 18. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Volume by Type (2017-2028)
Figure 19. Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2017-2028) & (USD/MT)
Figure 20. United States Radiopharmaceuticals in Nuclear Medicine Market Share by Type in 2022 & 2028
Figure 21. United States Radiopharmaceuticals in Nuclear Medicine Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. United States Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Value by Type (2017-2028)
Figure 23. United States Radiopharmaceuticals in Nuclear Medicine Sales by Type (2017-2028) & (K MT)
Figure 24. United States Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Volume by Type (2017-2028)
Figure 25. United States Radiopharmaceuticals in Nuclear Medicine Price by Type (2017-2028) & (USD/MT)
Figure 26. Product Picture of Diagnostic Application
Figure 27. Product Picture of Therapeutic Application
Figure 28. Product Picture of Research
Figure 29. Product Picture of Pharmaceutical
Figure 30. Product Picture of Other
Figure 31. Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application in 2022 & 2028
Figure 32. Global Radiopharmaceuticals in Nuclear Medicine Sales in Value by Application (2017-2028) & (US$ Million)
Figure 33. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Value by Application (2017-2028)
Figure 34. Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028) & (K MT)
Figure 35. Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Volume by Application (2017-2028)
Figure 36. Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2017-2028) & (USD/MT)
Figure 37. United States Radiopharmaceuticals in Nuclear Medicine Market Share by Application in 2022 & 2028
Figure 38. United States Radiopharmaceuticals in Nuclear Medicine Sales in Value by Application (2017-2028) & (US$ Million)
Figure 39. United States Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Value by Application (2017-2028)
Figure 40. United States Radiopharmaceuticals in Nuclear Medicine Sales by Application (2017-2028) & (K MT)
Figure 41. United States Radiopharmaceuticals in Nuclear Medicine Sales Market Share in Volume by Application (2017-2028)
Figure 42. United States Radiopharmaceuticals in Nuclear Medicine Price by Application (2017-2028) & (USD/MT)
Figure 43. North America Radiopharmaceuticals in Nuclear Medicine Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 44. North America Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 45. U.S. Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Canada Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. Europe Radiopharmaceuticals in Nuclear Medicine Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 48. Europe Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 49. Germany Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. France Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. U.K. Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Italy Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Russia Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 55. Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 56. China Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Japan Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. South Korea Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. India Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Australia Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Taiwan Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Indonesia Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Thailand Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Malaysia Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Philippines Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 67. Latin America Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 68. Mexico Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Brazil Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Argentina Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales in Volume Growth Rate 2017-2028 (K MT)
Figure 72. Middle East & Africa Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 73. Turkey Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Saudi Arabia Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. U.A.E Radiopharmaceuticals in Nuclear Medicine Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 76. Radiopharmaceuticals in Nuclear Medicine Value Chain
Figure 77. Radiopharmaceuticals in Nuclear Medicine Production Process
Figure 78. Channels of Distribution
Figure 79. Distributors Profiles
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
